Welcome to the September 2018 edition of our Updates on Myeloproliferative Neoplasms (MPNs) newsletter. This month, we highlight two articles on polycythemia vera concerning the role of JAK2 inhibition and cytoreductive therapy. We also explore myelofibrosis news, including ruxolitinib dose escalation to decrease adverse events and the potential of PTX3 plasma levels in determining disease burden. Additionally, we feature news articles on a new tool for patients with myelofibrosis undergoing stem cell transplantation and a study showing an increased risk of disease among relatives of patients with myeloid blood cancers.
And don’t forget about our other valuable MPN resources:
As always, I hope you find this month’s newsletter insightful and helpful for your everyday practice and beyond.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at firstname.lastname@example.org at any time.
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus